<ul>
<li>Codexis attended TIDES USA 2026 in Boston to present updates on its ECO Synthesis RNA manufacturing platform.     *      It disclosed full-length siRNA synthesis with phosphorothioate stereochemistry control, unveiled a single-nucleotide enzymatic initiation approach that could remove the need for chemically made starter oligonucleotides, and cited more than a 50% cut in global warming potential versus conventional methods. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200900PRIMZONEFULLFEED9723706) on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

CDXS

LABU

IBBQ

SBIO

<p>Codexis showcased its ECO Synthesis RNA manufacturing platform at TIDES USA 2026, highlighting advancements in siRNA synthesis with phosphorothioate stereochemistry control and a novel single-nucleotide enzymatic initiation method. The company reported over a 50% reduction in global warming potential compared to traditional methods.</p>

PUBT

Codexi

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Codexis spotlights siRNA stereochemistry control at TIDES USA 2026